Ocumetics Advances Clinical Program with Positive Six-Month Results, Eyes Group Two Surgeries in Q3 2026

Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) has announced a series of operational and clinical updates that underscore progress in its development of the Ocumetics Lens, an accommodating intraocular lens designed to restore vision after cataract surgery. The company reported positive six-month follow-up data from the first group of patients in its First-in-Human (FIH) study, which has enabled the advancement to Group Two surgeries scheduled for Q3 2026 in Mexico City.

The six-month results demonstrated encouraging safety and performance outcomes, with successful implantation procedures and favorable post-operative outcomes. Notably, one patient who was previously considered legally blind is now qualified to drive, highlighting the potential quality-of-life impact of the technology. These data have provided the foundation for Ocumetics to proceed to the next phase of its clinical study, a significant step toward commercialization.

To support completion of the FIH study and accelerate commercialization activities, the company has launched a financing initiative. Proceeds are expected to fund Group Two surgeries, finalize manufacturing and quality verification of clinical lenses, complete sterilization and packaging, advance regulatory and quality assurance programs, and continue strategic partnership initiatives. Management conducted over 50 one-on-one meetings with institutional investors, family offices, and strategic industry participants during recent investor conferences, reflecting growing recognition of the company's clinical progress.

Ocumetics has completed the design of its next-generation solid-state accommodating intraocular lens, which incorporates significant advancements in manufacturability, surgical handling, and accommodative performance. The redesigned lens features a simplified one-piece architecture that eliminates internal interface materials—no air, water, or oil—and is expected to improve manufacturing consistency and scalability. Manufacturing has commenced with the company's German partner, Amiplant GmbH, in preparation for Group Two surgeries.

All regulatory requirements necessary to proceed to Group Two patient enrollment have been successfully completed. The company is working closely with its clinical investigators, ethics committees, and regulatory consultants to finalize the remaining steps. Upon completion of manufacturing and product release activities, patient recruitment and surgical scheduling will begin.

Strategically, Ocumetics continues discussions with four of the world's seven largest ophthalmic companies regarding potential future partnerships and commercialization opportunities. Management has met with representatives from these organizations and received encouraging feedback. Several have expressed interest in reviewing additional clinical data following Group Two surgeries, with follow-up discussions tentatively scheduled for early Q4 2026 after one-month patient results are available.

The Group Two surgeries remain on track for Q3 2026 in Mexico City under the leadership of Principal Investigator Dr. Raphael Vasquez. Patients will receive the redesigned Ocumetics Lens delivered with an updated lens delivery system, incorporating improvements from preclinical work and feedback from the Group One experience. Management believes positive one-month results from Group Two will represent another meaningful value-creation milestone as the company advances toward larger clinical studies, regulatory submissions, and eventual commercialization.

With positive six-month clinical data, completion of the next-generation lens design, manufacturing underway, regulatory milestones achieved, and strategic discussions progressing, Ocumetics is positioned to execute the next phase of its clinical development strategy. The company remains focused on completing Group Two surgeries, advancing regulatory initiatives, and building strategic relationships to support long-term commercialization of the Ocumetics Lens.